nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Methylprednisolone—multiple sclerosis	0.0545	0.232	CbGbCtD
Carfilzomib—ABCB1—Mitoxantrone—multiple sclerosis	0.0398	0.169	CbGbCtD
Carfilzomib—ABCB1—Betamethasone—multiple sclerosis	0.0355	0.151	CbGbCtD
Carfilzomib—ABCB1—Prednisolone—multiple sclerosis	0.035	0.149	CbGbCtD
Carfilzomib—ABCB1—Prednisone—multiple sclerosis	0.033	0.141	CbGbCtD
Carfilzomib—ABCB1—Dexamethasone—multiple sclerosis	0.0206	0.0878	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—multiple sclerosis	0.0166	0.0705	CbGbCtD
Carfilzomib—PSMB10—nervous system—multiple sclerosis	0.00593	0.0621	CbGeAlD
Carfilzomib—Pentagastrin—BCHE—multiple sclerosis	0.00575	1	CrCbGaD
Carfilzomib—PSMB10—central nervous system—multiple sclerosis	0.00571	0.0598	CbGeAlD
Carfilzomib—PSMB10—cerebellum—multiple sclerosis	0.00558	0.0584	CbGeAlD
Carfilzomib—PSMB2—retina—multiple sclerosis	0.0053	0.0555	CbGeAlD
Carfilzomib—PSMB10—brain—multiple sclerosis	0.00453	0.0474	CbGeAlD
Carfilzomib—PSMB5—medulla oblongata—multiple sclerosis	0.00449	0.047	CbGeAlD
Carfilzomib—PSMB5—midbrain—multiple sclerosis	0.0041	0.043	CbGeAlD
Carfilzomib—PSMB5—spinal cord—multiple sclerosis	0.004	0.0419	CbGeAlD
Carfilzomib—PSMB1—medulla oblongata—multiple sclerosis	0.00392	0.0411	CbGeAlD
Carfilzomib—PSMB2—medulla oblongata—multiple sclerosis	0.00383	0.0401	CbGeAlD
Carfilzomib—PSMB1—midbrain—multiple sclerosis	0.00359	0.0376	CbGeAlD
Carfilzomib—PSMB2—midbrain—multiple sclerosis	0.0035	0.0367	CbGeAlD
Carfilzomib—PSMB1—spinal cord—multiple sclerosis	0.0035	0.0366	CbGeAlD
Carfilzomib—PSMB2—spinal cord—multiple sclerosis	0.00341	0.0358	CbGeAlD
Carfilzomib—PSMB5—cerebellum—multiple sclerosis	0.00317	0.0332	CbGeAlD
Carfilzomib—PSMB1—nervous system—multiple sclerosis	0.00295	0.0309	CbGeAlD
Carfilzomib—PSMB8—brain—multiple sclerosis	0.00292	0.0306	CbGeAlD
Carfilzomib—PSMB2—nervous system—multiple sclerosis	0.00288	0.0301	CbGeAlD
Carfilzomib—PSMB1—central nervous system—multiple sclerosis	0.00284	0.0297	CbGeAlD
Carfilzomib—PSMB1—cerebellum—multiple sclerosis	0.00278	0.0291	CbGeAlD
Carfilzomib—PSMB2—central nervous system—multiple sclerosis	0.00277	0.029	CbGeAlD
Carfilzomib—PSMB2—cerebellum—multiple sclerosis	0.00271	0.0284	CbGeAlD
Carfilzomib—PSMB5—brain—multiple sclerosis	0.00258	0.027	CbGeAlD
Carfilzomib—PSMB1—brain—multiple sclerosis	0.00225	0.0236	CbGeAlD
Carfilzomib—PSMB2—brain—multiple sclerosis	0.0022	0.023	CbGeAlD
Carfilzomib—Sepsis—Cladribine—multiple sclerosis	0.00207	0.00648	CcSEcCtD
Carfilzomib—Cardiac disorder—Fingolimod—multiple sclerosis	0.00196	0.00614	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Mitoxantrone—multiple sclerosis	0.00195	0.0061	CcSEcCtD
Carfilzomib—Hepatic failure—Cladribine—multiple sclerosis	0.00193	0.00603	CcSEcCtD
Carfilzomib—Renal failure acute—Cladribine—multiple sclerosis	0.00188	0.00587	CcSEcCtD
Carfilzomib—Lymphopenia—Prednisone—multiple sclerosis	0.00183	0.00572	CcSEcCtD
Carfilzomib—Back pain—Fingolimod—multiple sclerosis	0.00178	0.00557	CcSEcCtD
Carfilzomib—Pain in extremity—Cladribine—multiple sclerosis	0.00173	0.00542	CcSEcCtD
Carfilzomib—Neuritis—Prednisolone—multiple sclerosis	0.00172	0.00539	CcSEcCtD
Carfilzomib—Hypercalcaemia—Methylprednisolone—multiple sclerosis	0.0017	0.00532	CcSEcCtD
Carfilzomib—Bacterial infection—Methotrexate—multiple sclerosis	0.00169	0.0053	CcSEcCtD
Carfilzomib—Leukopenia—Fingolimod—multiple sclerosis	0.00165	0.00515	CcSEcCtD
Carfilzomib—Cough—Fingolimod—multiple sclerosis	0.00161	0.00502	CcSEcCtD
Carfilzomib—Hypertension—Fingolimod—multiple sclerosis	0.00159	0.00497	CcSEcCtD
Carfilzomib—Neuritis—Triamcinolone—multiple sclerosis	0.00159	0.00496	CcSEcCtD
Carfilzomib—Neuritis—Methylprednisolone—multiple sclerosis	0.00158	0.00495	CcSEcCtD
Carfilzomib—Hepatic failure—Azathioprine—multiple sclerosis	0.00157	0.0049	CcSEcCtD
Carfilzomib—Infection—Fingolimod—multiple sclerosis	0.00149	0.00467	CcSEcCtD
Carfilzomib—Neuritis—Betamethasone—multiple sclerosis	0.00144	0.0045	CcSEcCtD
Carfilzomib—Neuritis—Dexamethasone—multiple sclerosis	0.00144	0.0045	CcSEcCtD
Carfilzomib—Neutropenia—Cladribine—multiple sclerosis	0.0014	0.00438	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Cladribine—multiple sclerosis	0.00139	0.00435	CcSEcCtD
Carfilzomib—Sepsis—Mitoxantrone—multiple sclerosis	0.00136	0.00426	CcSEcCtD
Carfilzomib—Pneumonia—Cladribine—multiple sclerosis	0.00134	0.0042	CcSEcCtD
Carfilzomib—Dyspnoea—Fingolimod—multiple sclerosis	0.00134	0.00419	CcSEcCtD
Carfilzomib—Renal failure—Cladribine—multiple sclerosis	0.00131	0.00411	CcSEcCtD
Carfilzomib—Fatigue—Fingolimod—multiple sclerosis	0.0013	0.00405	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Mitoxantrone—multiple sclerosis	0.00126	0.00393	CcSEcCtD
Carfilzomib—Neuritis—Prednisone—multiple sclerosis	0.00125	0.00392	CcSEcCtD
Carfilzomib—Renal failure acute—Mitoxantrone—multiple sclerosis	0.00123	0.00386	CcSEcCtD
Carfilzomib—PSMB2—Azacitidine—Cladribine—multiple sclerosis	0.00122	0.0992	CbGdCrCtD
Carfilzomib—Oedema peripheral—Cladribine—multiple sclerosis	0.00118	0.00369	CcSEcCtD
Carfilzomib—Hyponatraemia—Mitoxantrone—multiple sclerosis	0.00114	0.00358	CcSEcCtD
Carfilzomib—Cardiac disorder—Cladribine—multiple sclerosis	0.00111	0.00348	CcSEcCtD
Carfilzomib—Pneumonia—Azathioprine—multiple sclerosis	0.00109	0.00342	CcSEcCtD
Carfilzomib—Asthenia—Fingolimod—multiple sclerosis	0.00108	0.00337	CcSEcCtD
Carfilzomib—Chills—Cladribine—multiple sclerosis	0.00108	0.00336	CcSEcCtD
Carfilzomib—Blood creatinine increased—Mitoxantrone—multiple sclerosis	0.00107	0.00334	CcSEcCtD
Carfilzomib—Hypokalaemia—Mitoxantrone—multiple sclerosis	0.00104	0.00324	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Prednisolone—multiple sclerosis	0.00103	0.00322	CcSEcCtD
Carfilzomib—Diarrhoea—Fingolimod—multiple sclerosis	0.00103	0.00322	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.00103	0.00321	CcSEcCtD
Carfilzomib—Back pain—Cladribine—multiple sclerosis	0.00101	0.00316	CcSEcCtD
Carfilzomib—Dizziness—Fingolimod—multiple sclerosis	0.000993	0.00311	CcSEcCtD
Carfilzomib—Anaemia—Cladribine—multiple sclerosis	0.000964	0.00302	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Triamcinolone—multiple sclerosis	0.000948	0.00296	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Methylprednisolone—multiple sclerosis	0.000945	0.00296	CcSEcCtD
Carfilzomib—Headache—Fingolimod—multiple sclerosis	0.000941	0.00294	CcSEcCtD
Carfilzomib—Neutropenia—Mitoxantrone—multiple sclerosis	0.00092	0.00288	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000915	0.00286	CcSEcCtD
Carfilzomib—Cough—Cladribine—multiple sclerosis	0.000911	0.00285	CcSEcCtD
Carfilzomib—Cardiac arrest—Prednisolone—multiple sclerosis	0.000889	0.00278	CcSEcCtD
Carfilzomib—Arthralgia—Cladribine—multiple sclerosis	0.000888	0.00278	CcSEcCtD
Carfilzomib—Hyperglycaemia—Mitoxantrone—multiple sclerosis	0.000888	0.00278	CcSEcCtD
Carfilzomib—Pneumonia—Mitoxantrone—multiple sclerosis	0.000883	0.00276	CcSEcCtD
Carfilzomib—Chills—Azathioprine—multiple sclerosis	0.000875	0.00274	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Mitoxantrone—multiple sclerosis	0.000865	0.00271	CcSEcCtD
Carfilzomib—Renal failure—Mitoxantrone—multiple sclerosis	0.000863	0.0027	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Betamethasone—multiple sclerosis	0.00086	0.00269	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Dexamethasone—multiple sclerosis	0.00086	0.00269	CcSEcCtD
Carfilzomib—Infection—Cladribine—multiple sclerosis	0.000846	0.00265	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cladribine—multiple sclerosis	0.000834	0.00261	CcSEcCtD
Carfilzomib—Cardiac arrest—Triamcinolone—multiple sclerosis	0.000817	0.00256	CcSEcCtD
Carfilzomib—Cardiac arrest—Methylprednisolone—multiple sclerosis	0.000815	0.00255	CcSEcCtD
Carfilzomib—Anorexia—Cladribine—multiple sclerosis	0.000812	0.00254	CcSEcCtD
Carfilzomib—Sepsis—Prednisone—multiple sclerosis	0.000812	0.00254	CcSEcCtD
Carfilzomib—ABCB1—retina—multiple sclerosis	0.000809	0.00848	CbGeAlD
Carfilzomib—Anaemia—Azathioprine—multiple sclerosis	0.000784	0.00245	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000776	0.00243	CcSEcCtD
Carfilzomib—Insomnia—Cladribine—multiple sclerosis	0.00077	0.00241	CcSEcCtD
Carfilzomib—Leukopenia—Azathioprine—multiple sclerosis	0.000759	0.00238	CcSEcCtD
Carfilzomib—Dyspnoea—Cladribine—multiple sclerosis	0.000759	0.00237	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Prednisone—multiple sclerosis	0.000749	0.00234	CcSEcCtD
Carfilzomib—Cardiac arrest—Betamethasone—multiple sclerosis	0.000741	0.00232	CcSEcCtD
Carfilzomib—Cardiac arrest—Dexamethasone—multiple sclerosis	0.000741	0.00232	CcSEcCtD
Carfilzomib—Decreased appetite—Cladribine—multiple sclerosis	0.00074	0.00232	CcSEcCtD
Carfilzomib—Fatigue—Cladribine—multiple sclerosis	0.000734	0.0023	CcSEcCtD
Carfilzomib—Pain—Cladribine—multiple sclerosis	0.000728	0.00228	CcSEcCtD
Carfilzomib—Constipation—Cladribine—multiple sclerosis	0.000728	0.00228	CcSEcCtD
Carfilzomib—Arthralgia—Azathioprine—multiple sclerosis	0.000722	0.00226	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Prednisolone—multiple sclerosis	0.00071	0.00222	CcSEcCtD
Carfilzomib—Hypokalaemia—Dexamethasone—multiple sclerosis	0.00071	0.00222	CcSEcCtD
Carfilzomib—Hypokalaemia—Betamethasone—multiple sclerosis	0.00071	0.00222	CcSEcCtD
Carfilzomib—Chills—Mitoxantrone—multiple sclerosis	0.000707	0.00221	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisolone—multiple sclerosis	0.000706	0.00221	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.00069	0.00216	CcSEcCtD
Carfilzomib—Infection—Azathioprine—multiple sclerosis	0.000688	0.00215	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—multiple sclerosis	0.000678	0.00212	CcSEcCtD
Carfilzomib—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000678	0.00212	CcSEcCtD
Carfilzomib—Body temperature increased—Cladribine—multiple sclerosis	0.000673	0.00211	CcSEcCtD
Carfilzomib—Back pain—Mitoxantrone—multiple sclerosis	0.000663	0.00208	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Triamcinolone—multiple sclerosis	0.000653	0.00204	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Methylprednisolone—multiple sclerosis	0.000651	0.00204	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Triamcinolone—multiple sclerosis	0.000649	0.00203	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Methylprednisolone—multiple sclerosis	0.000648	0.00203	CcSEcCtD
Carfilzomib—Cardiac arrest—Prednisone—multiple sclerosis	0.000646	0.00202	CcSEcCtD
Carfilzomib—Anaemia—Mitoxantrone—multiple sclerosis	0.000634	0.00198	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—multiple sclerosis	0.000631	0.00197	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000631	0.00197	CcSEcCtD
Carfilzomib—Hypokalaemia—Prednisone—multiple sclerosis	0.000618	0.00193	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—multiple sclerosis	0.000615	0.00192	CcSEcCtD
Carfilzomib—Leukopenia—Mitoxantrone—multiple sclerosis	0.000614	0.00192	CcSEcCtD
Carfilzomib—Asthenia—Cladribine—multiple sclerosis	0.000611	0.00191	CcSEcCtD
Carfilzomib—Hyperglycaemia—Dexamethasone—multiple sclerosis	0.000608	0.0019	CcSEcCtD
Carfilzomib—Hyperglycaemia—Betamethasone—multiple sclerosis	0.000608	0.0019	CcSEcCtD
Carfilzomib—Cough—Mitoxantrone—multiple sclerosis	0.000599	0.00187	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Dexamethasone—multiple sclerosis	0.000592	0.00185	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Betamethasone—multiple sclerosis	0.000592	0.00185	CcSEcCtD
Carfilzomib—Hypertension—Mitoxantrone—multiple sclerosis	0.000592	0.00185	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.000589	0.00184	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.000589	0.00184	CcSEcCtD
Carfilzomib—PSMB9—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000586	0.0477	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Methylprednisolone—multiple sclerosis	0.000586	0.0477	CbGdCrCtD
Carfilzomib—ABCB1—medulla oblongata—multiple sclerosis	0.000585	0.00613	CbGeAlD
Carfilzomib—Arthralgia—Mitoxantrone—multiple sclerosis	0.000584	0.00183	CcSEcCtD
Carfilzomib—Diarrhoea—Cladribine—multiple sclerosis	0.000583	0.00182	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Dexamethasone—multiple sclerosis	0.000576	0.047	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Betamethasone—multiple sclerosis	0.000576	0.047	CbGdCrCtD
Carfilzomib—Dizziness—Cladribine—multiple sclerosis	0.000563	0.00176	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Triamcinolone—multiple sclerosis	0.000563	0.0459	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Triamcinolone—multiple sclerosis	0.000563	0.0459	CbGdCrCtD
Carfilzomib—Infection—Mitoxantrone—multiple sclerosis	0.000556	0.00174	CcSEcCtD
Carfilzomib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00055	0.00172	CcSEcCtD
Carfilzomib—Neutropenia—Prednisone—multiple sclerosis	0.000549	0.00172	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000548	0.00171	CcSEcCtD
Carfilzomib—Body temperature increased—Azathioprine—multiple sclerosis	0.000547	0.00171	CcSEcCtD
Carfilzomib—Vomiting—Cladribine—multiple sclerosis	0.000541	0.00169	CcSEcCtD
Carfilzomib—ABCB1—midbrain—multiple sclerosis	0.000535	0.0056	CbGeAlD
Carfilzomib—PSMB9—Betamethasone—Prednisone—multiple sclerosis	0.000534	0.0435	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisone—multiple sclerosis	0.000534	0.0435	CbGdCrCtD
Carfilzomib—Anorexia—Mitoxantrone—multiple sclerosis	0.000534	0.00167	CcSEcCtD
Carfilzomib—Headache—Cladribine—multiple sclerosis	0.000534	0.00167	CcSEcCtD
Carfilzomib—Hyperglycaemia—Prednisone—multiple sclerosis	0.000529	0.00166	CcSEcCtD
Carfilzomib—ABCB1—spinal cord—multiple sclerosis	0.000522	0.00546	CbGeAlD
Carfilzomib—PSMB9—Dexamethasone—Prednisolone—multiple sclerosis	0.000522	0.0425	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Prednisolone—multiple sclerosis	0.000522	0.0425	CbGdCrCtD
Carfilzomib—Acute coronary syndrome—Prednisone—multiple sclerosis	0.000516	0.00161	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000513	0.0016	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00051	0.0016	CcSEcCtD
Carfilzomib—Nausea—Cladribine—multiple sclerosis	0.000506	0.00158	CcSEcCtD
Carfilzomib—Back pain—Triamcinolone—multiple sclerosis	0.000501	0.00157	CcSEcCtD
Carfilzomib—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000499	0.00156	CcSEcCtD
Carfilzomib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000487	0.00152	CcSEcCtD
Carfilzomib—Hypertension—Prednisolone—multiple sclerosis	0.000486	0.00152	CcSEcCtD
Carfilzomib—Fatigue—Mitoxantrone—multiple sclerosis	0.000483	0.00151	CcSEcCtD
Carfilzomib—Constipation—Mitoxantrone—multiple sclerosis	0.000479	0.0015	CcSEcCtD
Carfilzomib—Pain—Mitoxantrone—multiple sclerosis	0.000479	0.0015	CcSEcCtD
Carfilzomib—Diarrhoea—Azathioprine—multiple sclerosis	0.000474	0.00148	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—multiple sclerosis	0.000459	0.00143	CcSEcCtD
Carfilzomib—Dizziness—Azathioprine—multiple sclerosis	0.000458	0.00143	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Methylprednisolone—multiple sclerosis	0.000457	0.0373	CbGdCrCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000456	0.00143	CcSEcCtD
Carfilzomib—Cough—Triamcinolone—multiple sclerosis	0.000452	0.00141	CcSEcCtD
Carfilzomib—Hypertension—Triamcinolone—multiple sclerosis	0.000447	0.0014	CcSEcCtD
Carfilzomib—Hypertension—Methylprednisolone—multiple sclerosis	0.000446	0.00139	CcSEcCtD
Carfilzomib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000443	0.00138	CcSEcCtD
Carfilzomib—Vomiting—Azathioprine—multiple sclerosis	0.00044	0.00138	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—multiple sclerosis	0.00044	0.00138	CcSEcCtD
Carfilzomib—ABCB1—nervous system—multiple sclerosis	0.00044	0.0046	CbGeAlD
Carfilzomib—Arthralgia—Methylprednisolone—multiple sclerosis	0.00044	0.00137	CcSEcCtD
Carfilzomib—Headache—Azathioprine—multiple sclerosis	0.000434	0.00136	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—multiple sclerosis	0.00043	0.00134	CcSEcCtD
Carfilzomib—ABCB1—central nervous system—multiple sclerosis	0.000423	0.00443	CbGeAlD
Carfilzomib—Infection—Triamcinolone—multiple sclerosis	0.00042	0.00131	CcSEcCtD
Carfilzomib—Infection—Methylprednisolone—multiple sclerosis	0.000419	0.00131	CcSEcCtD
Carfilzomib—Insomnia—Prednisolone—multiple sclerosis	0.000415	0.0013	CcSEcCtD
Carfilzomib—ABCB1—cerebellum—multiple sclerosis	0.000414	0.00433	CbGeAlD
Carfilzomib—Nausea—Azathioprine—multiple sclerosis	0.000411	0.00129	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Prednisolone—multiple sclerosis	0.000407	0.0332	CbGdCrCtD
Carfilzomib—Hypertension—Betamethasone—multiple sclerosis	0.000405	0.00127	CcSEcCtD
Carfilzomib—Hypertension—Dexamethasone—multiple sclerosis	0.000405	0.00127	CcSEcCtD
Carfilzomib—Asthenia—Mitoxantrone—multiple sclerosis	0.000402	0.00126	CcSEcCtD
Carfilzomib—Pain—Prednisolone—multiple sclerosis	0.000393	0.00123	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000385	0.0012	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000384	0.0012	CcSEcCtD
Carfilzomib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000383	0.0012	CcSEcCtD
Carfilzomib—Insomnia—Triamcinolone—multiple sclerosis	0.000382	0.00119	CcSEcCtD
Carfilzomib—Insomnia—Methylprednisolone—multiple sclerosis	0.000381	0.00119	CcSEcCtD
Carfilzomib—Infection—Betamethasone—multiple sclerosis	0.000381	0.00119	CcSEcCtD
Carfilzomib—Infection—Dexamethasone—multiple sclerosis	0.000381	0.00119	CcSEcCtD
Carfilzomib—Anaemia—Prednisone—multiple sclerosis	0.000378	0.00118	CcSEcCtD
Carfilzomib—Dyspnoea—Triamcinolone—multiple sclerosis	0.000377	0.00118	CcSEcCtD
Carfilzomib—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000375	0.00117	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000375	0.00117	CcSEcCtD
Carfilzomib—Anorexia—Betamethasone—multiple sclerosis	0.000365	0.00114	CcSEcCtD
Carfilzomib—Anorexia—Dexamethasone—multiple sclerosis	0.000365	0.00114	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000364	0.00114	CcSEcCtD
Carfilzomib—Fatigue—Triamcinolone—multiple sclerosis	0.000364	0.00114	CcSEcCtD
Carfilzomib—Fatigue—Methylprednisolone—multiple sclerosis	0.000363	0.00114	CcSEcCtD
Carfilzomib—Pain—Triamcinolone—multiple sclerosis	0.000361	0.00113	CcSEcCtD
Carfilzomib—Vomiting—Mitoxantrone—multiple sclerosis	0.000356	0.00111	CcSEcCtD
Carfilzomib—Hypertension—Prednisone—multiple sclerosis	0.000353	0.0011	CcSEcCtD
Carfilzomib—Chills—Methotrexate—multiple sclerosis	0.000352	0.0011	CcSEcCtD
Carfilzomib—Headache—Mitoxantrone—multiple sclerosis	0.000351	0.0011	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000349	0.00109	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000349	0.00109	CcSEcCtD
Carfilzomib—Arthralgia—Prednisone—multiple sclerosis	0.000348	0.00109	CcSEcCtD
Carfilzomib—Insomnia—Betamethasone—multiple sclerosis	0.000347	0.00108	CcSEcCtD
Carfilzomib—Insomnia—Dexamethasone—multiple sclerosis	0.000347	0.00108	CcSEcCtD
Carfilzomib—ABCB1—brain—multiple sclerosis	0.000336	0.00352	CbGeAlD
Carfilzomib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000334	0.00104	CcSEcCtD
Carfilzomib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000333	0.00104	CcSEcCtD
Carfilzomib—Decreased appetite—Betamethasone—multiple sclerosis	0.000333	0.00104	CcSEcCtD
Carfilzomib—Nausea—Mitoxantrone—multiple sclerosis	0.000333	0.00104	CcSEcCtD
Carfilzomib—Infection—Prednisone—multiple sclerosis	0.000332	0.00104	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Methylprednisolone—multiple sclerosis	0.000331	0.027	CbGdCrCtD
Carfilzomib—Back pain—Methotrexate—multiple sclerosis	0.000331	0.00103	CcSEcCtD
Carfilzomib—Fatigue—Dexamethasone—multiple sclerosis	0.00033	0.00103	CcSEcCtD
Carfilzomib—Fatigue—Betamethasone—multiple sclerosis	0.00033	0.00103	CcSEcCtD
Carfilzomib—Pain—Betamethasone—multiple sclerosis	0.000328	0.00102	CcSEcCtD
Carfilzomib—Pain—Dexamethasone—multiple sclerosis	0.000328	0.00102	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Dexamethasone—multiple sclerosis	0.000326	0.0266	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Betamethasone—multiple sclerosis	0.000326	0.0266	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Triamcinolone—multiple sclerosis	0.000318	0.0259	CbGdCrCtD
Carfilzomib—Anorexia—Prednisone—multiple sclerosis	0.000318	0.000995	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—multiple sclerosis	0.000316	0.000988	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—multiple sclerosis	0.000306	0.000957	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000304	0.000951	CcSEcCtD
Carfilzomib—Dizziness—Prednisolone—multiple sclerosis	0.000304	0.00095	CcSEcCtD
Carfilzomib—Asthenia—Triamcinolone—multiple sclerosis	0.000303	0.000948	CcSEcCtD
Carfilzomib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000303	0.000947	CcSEcCtD
Carfilzomib—Body temperature increased—Betamethasone—multiple sclerosis	0.000303	0.000947	CcSEcCtD
Carfilzomib—Asthenia—Methylprednisolone—multiple sclerosis	0.000302	0.000946	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisone—multiple sclerosis	0.000302	0.0246	CbGdCrCtD
Carfilzomib—Insomnia—Prednisone—multiple sclerosis	0.000302	0.000944	CcSEcCtD
Carfilzomib—Cough—Methotrexate—multiple sclerosis	0.000298	0.000933	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisolone—multiple sclerosis	0.000295	0.024	CbGdCrCtD
Carfilzomib—Arthralgia—Methotrexate—multiple sclerosis	0.000291	0.00091	CcSEcCtD
Carfilzomib—Decreased appetite—Prednisone—multiple sclerosis	0.00029	0.000907	CcSEcCtD
Carfilzomib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000288	0.000902	CcSEcCtD
Carfilzomib—Fatigue—Prednisone—multiple sclerosis	0.000288	0.0009	CcSEcCtD
Carfilzomib—Headache—Prednisolone—multiple sclerosis	0.000288	0.0009	CcSEcCtD
Carfilzomib—Constipation—Prednisone—multiple sclerosis	0.000285	0.000893	CcSEcCtD
Carfilzomib—Dizziness—Triamcinolone—multiple sclerosis	0.000279	0.000874	CcSEcCtD
Carfilzomib—Dizziness—Methylprednisolone—multiple sclerosis	0.000279	0.000872	CcSEcCtD
Carfilzomib—Infection—Methotrexate—multiple sclerosis	0.000277	0.000867	CcSEcCtD
Carfilzomib—Asthenia—Betamethasone—multiple sclerosis	0.000275	0.00086	CcSEcCtD
Carfilzomib—Asthenia—Dexamethasone—multiple sclerosis	0.000275	0.00086	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000273	0.000854	CcSEcCtD
Carfilzomib—Nausea—Prednisolone—multiple sclerosis	0.000273	0.000853	CcSEcCtD
Carfilzomib—Vomiting—Triamcinolone—multiple sclerosis	0.000269	0.00084	CcSEcCtD
Carfilzomib—Vomiting—Methylprednisolone—multiple sclerosis	0.000268	0.000838	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—multiple sclerosis	0.000266	0.000832	CcSEcCtD
Carfilzomib—Headache—Triamcinolone—multiple sclerosis	0.000265	0.000828	CcSEcCtD
Carfilzomib—Headache—Methylprednisolone—multiple sclerosis	0.000264	0.000826	CcSEcCtD
Carfilzomib—Body temperature increased—Prednisone—multiple sclerosis	0.000264	0.000825	CcSEcCtD
Carfilzomib—Diarrhoea—Betamethasone—multiple sclerosis	0.000262	0.00082	CcSEcCtD
Carfilzomib—Diarrhoea—Dexamethasone—multiple sclerosis	0.000262	0.00082	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000254	0.000795	CcSEcCtD
Carfilzomib—Dizziness—Dexamethasone—multiple sclerosis	0.000253	0.000793	CcSEcCtD
Carfilzomib—Dizziness—Betamethasone—multiple sclerosis	0.000253	0.000793	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—multiple sclerosis	0.000252	0.000789	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Methylprednisolone—multiple sclerosis	0.000252	0.0205	CbGdCrCtD
Carfilzomib—Nausea—Triamcinolone—multiple sclerosis	0.000251	0.000785	CcSEcCtD
Carfilzomib—Nausea—Methylprednisolone—multiple sclerosis	0.00025	0.000783	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—multiple sclerosis	0.000249	0.000778	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Dexamethasone—multiple sclerosis	0.000248	0.0202	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Betamethasone—multiple sclerosis	0.000248	0.0202	CbGdCrCtD
Carfilzomib—Vomiting—Betamethasone—multiple sclerosis	0.000244	0.000762	CcSEcCtD
Carfilzomib—Vomiting—Dexamethasone—multiple sclerosis	0.000244	0.000762	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Triamcinolone—multiple sclerosis	0.000243	0.0198	CbGdCrCtD
Carfilzomib—Decreased appetite—Methotrexate—multiple sclerosis	0.000242	0.000758	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—multiple sclerosis	0.00024	0.000752	CcSEcCtD
Carfilzomib—Headache—Dexamethasone—multiple sclerosis	0.00024	0.000751	CcSEcCtD
Carfilzomib—Headache—Betamethasone—multiple sclerosis	0.00024	0.000751	CcSEcCtD
Carfilzomib—Asthenia—Prednisone—multiple sclerosis	0.000239	0.000749	CcSEcCtD
Carfilzomib—Pain—Methotrexate—multiple sclerosis	0.000239	0.000746	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisone—multiple sclerosis	0.00023	0.0188	CbGdCrCtD
Carfilzomib—Diarrhoea—Prednisone—multiple sclerosis	0.000228	0.000714	CcSEcCtD
Carfilzomib—Nausea—Dexamethasone—multiple sclerosis	0.000228	0.000712	CcSEcCtD
Carfilzomib—Nausea—Betamethasone—multiple sclerosis	0.000228	0.000712	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Prednisolone—multiple sclerosis	0.000225	0.0183	CbGdCrCtD
Carfilzomib—Dizziness—Prednisone—multiple sclerosis	0.000221	0.00069	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—multiple sclerosis	0.00022	0.00069	CcSEcCtD
Carfilzomib—Vomiting—Prednisone—multiple sclerosis	0.000212	0.000664	CcSEcCtD
Carfilzomib—Headache—Prednisone—multiple sclerosis	0.000209	0.000654	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—multiple sclerosis	0.0002	0.000626	CcSEcCtD
Carfilzomib—Nausea—Prednisone—multiple sclerosis	0.000198	0.00062	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—multiple sclerosis	0.000191	0.000597	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—multiple sclerosis	0.000184	0.000577	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—multiple sclerosis	0.000177	0.000555	CcSEcCtD
Carfilzomib—Headache—Methotrexate—multiple sclerosis	0.000175	0.000546	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—multiple sclerosis	0.000166	0.000518	CcSEcCtD
Carfilzomib—PSMB8—Dexamethasone—Methylprednisolone—multiple sclerosis	0.000135	0.011	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Methylprednisolone—multiple sclerosis	0.000135	0.011	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Betamethasone—multiple sclerosis	0.000133	0.0108	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Dexamethasone—multiple sclerosis	0.000133	0.0108	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Triamcinolone—multiple sclerosis	0.00013	0.0106	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Triamcinolone—multiple sclerosis	0.00013	0.0106	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisone—multiple sclerosis	0.000123	0.0101	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisone—multiple sclerosis	0.000123	0.0101	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisolone—multiple sclerosis	0.00012	0.00982	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisolone—multiple sclerosis	0.00012	0.00982	CbGdCrCtD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	5.16e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SPP1—multiple sclerosis	5.16e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SPP1—multiple sclerosis	5.14e-05	0.000155	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IFNG—multiple sclerosis	5.05e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ICAM1—multiple sclerosis	5.03e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ICAM1—multiple sclerosis	5.03e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ICAM1—multiple sclerosis	5.03e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IFNG—multiple sclerosis	5.03e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCR5—multiple sclerosis	5.02e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCR5—multiple sclerosis	5e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TYK2—multiple sclerosis	4.98e-05	0.00015	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ICAM1—multiple sclerosis	4.96e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TYK2—multiple sclerosis	4.96e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2RA—multiple sclerosis	4.95e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—APOE—multiple sclerosis	4.94e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—APOE—multiple sclerosis	4.94e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—APOE—multiple sclerosis	4.94e-05	0.000149	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2RA—multiple sclerosis	4.93e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL10—multiple sclerosis	4.91e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL10—multiple sclerosis	4.91e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL10—multiple sclerosis	4.91e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CD4—multiple sclerosis	4.88e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—APOE—multiple sclerosis	4.87e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD4—multiple sclerosis	4.85e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD80—multiple sclerosis	4.84e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD80—multiple sclerosis	4.84e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD80—multiple sclerosis	4.84e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL10—multiple sclerosis	4.84e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MYC—multiple sclerosis	4.79e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MYC—multiple sclerosis	4.79e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MYC—multiple sclerosis	4.79e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD80—multiple sclerosis	4.77e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MYC—multiple sclerosis	4.72e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—POMC—multiple sclerosis	4.69e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MAPK1—multiple sclerosis	4.68e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MAPK1—multiple sclerosis	4.68e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MAPK1—multiple sclerosis	4.68e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—POMC—multiple sclerosis	4.67e-05	0.000141	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP27B1—multiple sclerosis	4.65e-05	0.00014	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP24A1—multiple sclerosis	4.65e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MAPK1—multiple sclerosis	4.62e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—APOE—multiple sclerosis	4.57e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—APOE—multiple sclerosis	4.55e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL1B—multiple sclerosis	4.5e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CD4—multiple sclerosis	4.5e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL2—multiple sclerosis	4.49e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL1B—multiple sclerosis	4.48e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CD4—multiple sclerosis	4.48e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CD80—multiple sclerosis	4.47e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CD80—multiple sclerosis	4.47e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CD80—multiple sclerosis	4.47e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL2—multiple sclerosis	4.47e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CD80—multiple sclerosis	4.41e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CD86—multiple sclerosis	4.29e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CD86—multiple sclerosis	4.29e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CD86—multiple sclerosis	4.29e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—ALB—multiple sclerosis	4.28e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—ALB—multiple sclerosis	4.26e-05	0.000128	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GPC5—multiple sclerosis	4.26e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CD86—multiple sclerosis	4.23e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL5—multiple sclerosis	4.22e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL5—multiple sclerosis	4.22e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL5—multiple sclerosis	4.22e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL5—multiple sclerosis	4.16e-05	0.000126	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—APOE—multiple sclerosis	4.14e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—APOE—multiple sclerosis	4.14e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—APOE—multiple sclerosis	4.14e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CD80—multiple sclerosis	4.13e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CD80—multiple sclerosis	4.11e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—TYK2—multiple sclerosis	4.09e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—TYK2—multiple sclerosis	4.09e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—TYK2—multiple sclerosis	4.09e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—APOE—multiple sclerosis	4.08e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—TYK2—multiple sclerosis	4.03e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—POMC—multiple sclerosis	3.92e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SPP1—multiple sclerosis	3.91e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SPP1—multiple sclerosis	3.91e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SPP1—multiple sclerosis	3.91e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—POMC—multiple sclerosis	3.91e-05	0.000118	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SPP1—multiple sclerosis	3.86e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCL2—multiple sclerosis	3.84e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IFNG—multiple sclerosis	3.83e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IFNG—multiple sclerosis	3.83e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IFNG—multiple sclerosis	3.83e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCL2—multiple sclerosis	3.82e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCR5—multiple sclerosis	3.81e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCR5—multiple sclerosis	3.81e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCR5—multiple sclerosis	3.81e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—STAT3—multiple sclerosis	3.78e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TYK2—multiple sclerosis	3.77e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TYK2—multiple sclerosis	3.77e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TYK2—multiple sclerosis	3.77e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IFNG—multiple sclerosis	3.77e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—STAT3—multiple sclerosis	3.76e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCR5—multiple sclerosis	3.75e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2RA—multiple sclerosis	3.75e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2RA—multiple sclerosis	3.75e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2RA—multiple sclerosis	3.75e-05	0.000113	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TYK2—multiple sclerosis	3.72e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2RA—multiple sclerosis	3.7e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD4—multiple sclerosis	3.7e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD4—multiple sclerosis	3.7e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD4—multiple sclerosis	3.7e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD4—multiple sclerosis	3.64e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—POMC—multiple sclerosis	3.56e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—POMC—multiple sclerosis	3.56e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—POMC—multiple sclerosis	3.56e-05	0.000107	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—RRM1—multiple sclerosis	3.53e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—POMC—multiple sclerosis	3.51e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MYC—multiple sclerosis	3.49e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TYK2—multiple sclerosis	3.49e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—STAT3—multiple sclerosis	3.49e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MYC—multiple sclerosis	3.47e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TYK2—multiple sclerosis	3.47e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—STAT3—multiple sclerosis	3.47e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—APOE—multiple sclerosis	3.46e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—APOE—multiple sclerosis	3.46e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—APOE—multiple sclerosis	3.46e-05	0.000104	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—MAPK1—multiple sclerosis	3.43e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—MAPK1—multiple sclerosis	3.42e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL1B—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL1B—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL1B—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APOE—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CD4—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CD4—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CD4—multiple sclerosis	3.41e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—multiple sclerosis	3.4e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—multiple sclerosis	3.4e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—multiple sclerosis	3.4e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL1B—multiple sclerosis	3.37e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CD4—multiple sclerosis	3.36e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—multiple sclerosis	3.35e-05	0.000101	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.25e-05	9.8e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.25e-05	9.78e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—ALB—multiple sclerosis	3.24e-05	9.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—ALB—multiple sclerosis	3.24e-05	9.77e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—ALB—multiple sclerosis	3.24e-05	9.77e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MYC—multiple sclerosis	3.24e-05	9.76e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TGFB1—multiple sclerosis	3.23e-05	9.74e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MYC—multiple sclerosis	3.22e-05	9.72e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TGFB1—multiple sclerosis	3.22e-05	9.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—ALB—multiple sclerosis	3.2e-05	9.64e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.18e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MAPK1—multiple sclerosis	3.17e-05	9.55e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MAPK1—multiple sclerosis	3.15e-05	9.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CD80—multiple sclerosis	3.13e-05	9.43e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CD80—multiple sclerosis	3.13e-05	9.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CD80—multiple sclerosis	3.13e-05	9.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CD80—multiple sclerosis	3.09e-05	9.3e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.03e-05	9.13e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—POMC—multiple sclerosis	2.97e-05	8.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—POMC—multiple sclerosis	2.97e-05	8.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—POMC—multiple sclerosis	2.97e-05	8.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—POMC—multiple sclerosis	2.93e-05	8.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCL2—multiple sclerosis	2.91e-05	8.77e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCL2—multiple sclerosis	2.91e-05	8.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCL2—multiple sclerosis	2.91e-05	8.77e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—multiple sclerosis	2.9e-05	8.74e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—multiple sclerosis	2.89e-05	8.7e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCL2—multiple sclerosis	2.87e-05	8.65e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—multiple sclerosis	2.86e-05	8.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—multiple sclerosis	2.86e-05	8.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—multiple sclerosis	2.86e-05	8.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—multiple sclerosis	2.82e-05	8.5e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—multiple sclerosis	2.75e-05	8.28e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—multiple sclerosis	2.73e-05	8.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—multiple sclerosis	2.64e-05	7.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—multiple sclerosis	2.64e-05	7.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—multiple sclerosis	2.64e-05	7.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TYK2—multiple sclerosis	2.64e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TYK2—multiple sclerosis	2.64e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TYK2—multiple sclerosis	2.64e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—multiple sclerosis	2.64e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—multiple sclerosis	2.64e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—multiple sclerosis	2.64e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—multiple sclerosis	2.64e-05	7.95e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—multiple sclerosis	2.63e-05	7.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—multiple sclerosis	2.61e-05	7.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TYK2—multiple sclerosis	2.61e-05	7.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—multiple sclerosis	2.61e-05	7.85e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK1—multiple sclerosis	2.6e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK1—multiple sclerosis	2.6e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK1—multiple sclerosis	2.6e-05	7.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK1—multiple sclerosis	2.57e-05	7.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—multiple sclerosis	2.46e-05	7.4e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—multiple sclerosis	2.46e-05	7.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—multiple sclerosis	2.46e-05	7.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—multiple sclerosis	2.45e-05	7.38e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—multiple sclerosis	2.45e-05	7.38e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—multiple sclerosis	2.45e-05	7.38e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—multiple sclerosis	2.44e-05	7.36e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—multiple sclerosis	2.44e-05	7.34e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—multiple sclerosis	2.43e-05	7.32e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—multiple sclerosis	2.42e-05	7.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—multiple sclerosis	2.42e-05	7.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—multiple sclerosis	2.41e-05	7.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK1—multiple sclerosis	2.4e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK1—multiple sclerosis	2.4e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK1—multiple sclerosis	2.4e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK1—multiple sclerosis	2.37e-05	7.14e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—multiple sclerosis	2.27e-05	6.84e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—multiple sclerosis	2.26e-05	6.82e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—multiple sclerosis	2.26e-05	6.8e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—multiple sclerosis	2.25e-05	6.79e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK1—multiple sclerosis	2.22e-05	6.69e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK1—multiple sclerosis	2.21e-05	6.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—multiple sclerosis	2.2e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—multiple sclerosis	2.2e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—multiple sclerosis	2.2e-05	6.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—multiple sclerosis	2.17e-05	6.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—multiple sclerosis	2.08e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—multiple sclerosis	2.08e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—multiple sclerosis	2.08e-05	6.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—multiple sclerosis	2.05e-05	6.18e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.04e-05	6.14e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—BCHE—multiple sclerosis	2.03e-05	6.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—multiple sclerosis	2e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—multiple sclerosis	2e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—multiple sclerosis	2e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—multiple sclerosis	1.97e-05	5.94e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—multiple sclerosis	1.85e-05	5.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—multiple sclerosis	1.85e-05	5.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—multiple sclerosis	1.85e-05	5.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—multiple sclerosis	1.85e-05	5.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—multiple sclerosis	1.85e-05	5.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—multiple sclerosis	1.85e-05	5.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—multiple sclerosis	1.82e-05	5.5e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—multiple sclerosis	1.82e-05	5.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—multiple sclerosis	1.72e-05	5.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—multiple sclerosis	1.72e-05	5.18e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—multiple sclerosis	1.72e-05	5.18e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—multiple sclerosis	1.72e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—multiple sclerosis	1.72e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—multiple sclerosis	1.72e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—multiple sclerosis	1.71e-05	5.14e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—multiple sclerosis	1.7e-05	5.12e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—multiple sclerosis	1.7e-05	5.11e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—multiple sclerosis	1.69e-05	5.1e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK1—multiple sclerosis	1.68e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK1—multiple sclerosis	1.68e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK1—multiple sclerosis	1.68e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK1—multiple sclerosis	1.66e-05	5e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—multiple sclerosis	1.29e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—multiple sclerosis	1.29e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—multiple sclerosis	1.29e-05	3.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—multiple sclerosis	1.27e-05	3.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOE—multiple sclerosis	1.22e-05	3.67e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—POMC—multiple sclerosis	1.05e-05	3.15e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—multiple sclerosis	9.54e-06	2.88e-05	CbGpPWpGaD
